Roswell Park Newsroom

For media inquires about CIMAvax lung cancer vaccine, please fill out a Media Request Form.

Media Request Form

Press Releases

Roswell Park’s Dr. Theresa Hahn to present study that may lead to better patient outcomes at BMT Tandem Meeting
Wednesday, February 22, 2017

Blood and marrow transplantation (BMT) is a standard therapy used to treat leukemias and other life-threatening blood diseases. A Roswell Park Cancer Institute-led team has identified genetic variations in the DNA of both transplant recipients and their unrelated cell donors that were associated with poor patient outcomes.

Expert Database

Roswell Park Public Affairs

Annie Deck-Miller
Senior Media Relations Manager
716-845-8593
Annie.Deck-Miller@roswellpark.org
Deb Pettibone
Public Information Specialist
716-845-4919
Deborah.Pettibone@roswellpark.org

Roswell Park Alliance Foundation

Amy Biber
Director, Development Marketing And Communications
716-845-1038
Amy.Biber@RoswellPark.org

 

News In Brief

Thursday, November 3, 2016
Immunotherapy, which uses the body’s own immune system to fight disease, is transforming the treatment of several types of cancers. Severe adverse effects can result from these groundbreaking cancer treatments, however, and when they do, it’s important to recognize and quickly address them, researchers write in the New England Journal of Medicine.

Cancer Talk Blog

Thursday, February 23, 2017 - 5:00pm
Director of the Blood and Marrow Transplant Center at Roswell Park, Philip McCarthy, MD.

The U.S. Food and Drug Administration approved a new indication for the oral drug lenalidomide (brand name Revlimid) as a maintenance therapy for multiple myeloma patients following autologous hematopoietic stem cell transplant (ASCT), also known as autologous blood and marrow transplant (BMT).

Wednesday, February 22, 2017